TITLE:
Drug therapy: Solamargine and other solasodine rhamnosyl glycosides as anticancer agents
AUTHORS:
Bill E. Cham
KEYWORDS:
Cancer; Skin Cancer; Solamargine; Solasonine; BEC; Solasodine Rhamnosyl Glycosides; CuradermBEC5; Apoptosis; Antineoplastic; Targeted Therapy
JOURNAL NAME:
Modern Chemotherapy,
Vol.2 No.2,
April
29,
2013
ABSTRACT: In the last century,
the discovery of cytotoxic agents was revolutionary for anticancer therapy. These
therapies have resulted in better understanding of cancer in general. However,
the development of agents that combine efficacy, safety and convenience
remains a great challenge. The narrow, if not adverse, therapeutic index of
most drugs, the damage not only to cancer cells, but also to normal and healthy
tissue and the occurrence of resistance have limited anticancer efficacy. This
review presents the development of promising novel cytotoxic solasodine rhamnosyl
glycoside drugs that offer not only gains in specificity and efficacy, but also
in safety, tolerability, non-resistance and convenience in the treatment of patients
with cancer.